Retrovirally marked CD34-enriched peripheral blood and bone marrow cells contribute to long-term engraftment after autologous transplantation.

We report here on a preliminary human autologous transplantation study of retroviral gene transfer to bone marrow (BM) and peripheral blood (PB)-derived CD34-enriched cells. Eleven patients with multiple myeloma or breast cancer had cyclophosphamide and filgrastim-mobilized PB cells CD34-enriched and transduced with a retroviral marking vector containing the neomycin resistance gene, and CD34-enriched BM cells transduced with a second marking vector also containing a neomycin resistance gene. After high-dose conditioning therapy, both transduced cell populations were reinfused and patients were followed over time for the presence of the marker gene and any adverse effects related to the gene-transfer procedure. All 10 evaluable patients had the marker gene detected at the time of engraftment, and 3 of 9 patients had persistence of the marker gene for greater than 18 months posttransplantation. The marker gene was detected in multiple lineages, including granulocytes, T cells, and B cells. The source of the marking was both the transduced PB graft and the BM graft, with a suggestion of better long-term marking originating from the PB graft. The steady-state levels of marking were low, with only 1:1000 to 1:10,000 cells positive. There was no toxicity noted, and patients did not develop detectable replication-competent helper virus at any time posttransplantation. These results suggest that mobilized PB cells may be preferable to BM for gene therapy applications and that progeny of mobilized peripheral blood cells can contribute long-term to engraftment of multiple lineages.

[1]  J. O’Shaughnessy,et al.  Positive selection of CD34+ hematopoietic cells using an immunoaffinity column results in T cell-depletion equivalent to elutriation. , 1995, Experimental hematology.

[2]  Rill,et al.  Direct demonstration that autologous bone marrow transplantation for solid tumors can return a multiplicity of tumorigenic cells. , 1994, Blood.

[3]  N. Schmitz,et al.  G‐CSF‐mobilized peripheral blood progenitor cells for allogeneic transplantation: safety, kinetics of mobilization, and composition of the graft , 1994, British journal of haematology.

[4]  C. Eaves,et al.  Kinetics of committed and primitive blood progenitor mobilization after chemotherapy and growth factor treatment and their use in autotransplants. , 1994, Blood.

[5]  David A. Williams,et al.  Bone marrow extracellular matrix molecules improve gene transfer into human hematopoietic cells via retroviral vectors. , 1994, The Journal of clinical investigation.

[6]  E. Shpall,et al.  Transplantation of enriched CD34-positive autologous marrow into breast cancer patients following high-dose chemotherapy: influence of CD34-positive peripheral-blood progenitors and growth factors on engraftment. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  J. Ihle,et al.  Gene marking to determine whether autologous marrow infusion restores long-term haemopoiesis in cancer patients , 1993, The Lancet.

[8]  D. Crowther,et al.  Transplantation potential of hematopoietic cells released into the circulation during routine chemotherapy for non-Hodgkin's lymphoma. , 1993, Blood.

[9]  P. Quesenberry,et al.  Long-term engraftment of normal and post-5-fluorouracil murine marrow into normal nonmyeloablated mice. , 1993, Blood.

[10]  R. Mulligan,et al.  The basic science of gene therapy. , 1993, Science.

[11]  A. Nienhuis,et al.  Amendment to clinical research projects. Genetic marking with retroviral vectors to study the feasibility of stem cell gene transfer and the biology of hematopoietic reconstitution after autologous transplantation in multiple myeloma, chronic myelogenous leukemia, or metastatic breast cancer. , 1993, Human gene therapy.

[12]  C. Dunbar,et al.  Retroviral-mediated gene transfer into CD34-enriched human peripheral blood stem cells. , 1993, Experimental hematology.

[13]  A. Howell,et al.  Haemopoietic cells mobilised into the circulation by lenograstim as alternative to bone marrow for allogeneic transplants , 1993, The Lancet.

[14]  A. Keating,et al.  Hematopoietic stem cells engraft in untreated transplant recipients. , 1993, Experimental hematology.

[15]  W. Anderson,et al.  Gene-marking to trace origin of relapse after autologous bone-marrow transplantation , 1993, The Lancet.

[16]  C. Eaves.  Peripheral blood stem cells reach new heights. , 1993, Blood.

[17]  M. Raffeld,et al.  Helper virus induced T cell lymphoma in nonhuman primates after retroviral mediated gene transfer , 1992, The Journal of experimental medicine.

[18]  D. Valerio,et al.  Long-term expression of human adenosine deaminase in rhesus monkeys transplanted with retrovirus-infected bone-marrow cells. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[19]  I. Pastan,et al.  Selection of drug-resistant bone marrow cells in vivo after retroviral transfer of human MDR1. , 1992, Science.

[20]  A. Miller,et al.  Human gene therapy comes of age , 1992, Nature.

[21]  C. Eaves,et al.  Retroviral gene transfer to primitive normal and leukemic hematopoietic cells using clinically applicable procedures. , 1992, The Journal of clinical investigation.

[22]  J. Belmont,et al.  Stromal support enhances cell-free retroviral vector transduction of human bone marrow long-term culture-initiating cells. , 1992, Blood.

[23]  S. Kamel‐Reid,et al.  Autologous transplantation of canine long-term marrow culture cells genetically marked by retroviral vectors. , 1992, Blood.

[24]  I. Tabbara,et al.  Peripheral hematopoietic stem cell transplantation: current concepts. , 1992, Experimental hematology.

[25]  G. Bonadonna,et al.  Human peripheral blood hematopoietic progenitors are optimal targets of retroviral-mediated gene transfer. , 1992, Blood.

[26]  S. Karlsson,et al.  High levels of human glucocerebrosidase activity in macrophages of long-term reconstituted mice after retroviral infection of hematopoietic stem cells. , 1992, Blood.

[27]  S. Karlsson,et al.  Treatment of genetic defects in hematopoietic cell function by gene transfer. , 1991, Blood.

[28]  F. Appelbaum,et al.  Retrovirus-mediated gene transduction into long-term repopulating marrow cells of dogs. , 1991, Blood.

[29]  T. Spitzer,et al.  Automated processing of human bone marrow can result in a population of mononuclear cells capable of achieving engraftment following transplantation , 1991, Transfusion.

[30]  K. Cornetta,et al.  Safety issues related to retroviral-mediated gene transfer in humans. , 1991, Human gene therapy.

[31]  A. Nienhuis,et al.  Survival and retrovirus infection of murine hematopoietic stem cells in vitro: effects of 5-FU and method of infection. , 1991, Experimental hematology.

[32]  I. Bernstein,et al.  Engraftment after infusion of CD34+ marrow cells in patients with breast cancer or neuroblastoma. , 1991, Blood.

[33]  D. Kohn,et al.  Comparison of the effects of growth factors on retroviral vector-mediated gene transfer and the proliferative status of human hematopoietic progenitor cells. , 1990, Human gene therapy.

[34]  A. Miller,et al.  Gene transfer by retrovirus vectors occurs only in cells that are actively replicating at the time of infection , 1990, Molecular and cellular biology.

[35]  A. Nienhuis,et al.  Development of a high-titer retrovirus producer cell line capable of gene transfer into rhesus monkey hematopoietic stem cells. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[36]  A. Kessinger.  Autologous transplantation with peripheral blood stem cells: a review of clinical results. , 1990, Journal of clinical apheresis.

[37]  C. Eaves,et al.  Retrovirus-mediated gene transfer to purified hemopoietic stem cells with long-term lympho-myelopoietic repopulating ability. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[38]  D. Weisenburger,et al.  Allogeneic transplantation of blood-derived, T cell-depleted hemopoietic stem cells after myeloablative treatment in a patient with acute lymphoblastic leukemia. , 1989, Bone marrow transplantation.

[39]  David A. Williams,et al.  Long-term expression of human adenosine deaminase in mice transplanted with retrovirus-infected hematopoietic stem cells. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[40]  R. Marcus,et al.  Autografting for patients with chronic myeloid leukaemia in chronic phase: peripheral blood stem cells may have a finite capacity for maintaining haemopoiesis , 1989, British journal of haematology.

[41]  R. Storb,et al.  Improved retroviral transfer of genes into canine hematopoietic progenitor cells kept in long-term marrow culture. , 1989, Blood.

[42]  P. Kantoff,et al.  Expression of human adenosine deaminase in nonhuman primates after retrovirus-mediated gene transfer , 1987, The Journal of experimental medicine.

[43]  A. Miller,et al.  Redesign of retrovirus packaging cell lines to avoid recombination leading to helper virus production , 1986, Molecular and cellular biology.

[44]  D. A. Quarles,et al.  Progress and problems , 1953, Electrical Engineering.